- Home
- GNW vs DNLI Comparison
GNW vs DNLI Comparison
Compare GNW & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | DNLI |
|---|---|---|
| Founded | 1871 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GNW | DNLI |
|---|---|---|
| Price | $8.29 | $21.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $10.00 | ★ $31.58 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.86 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $7,299,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,975.30 |
| P/E Ratio | $14.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.99 | $10.57 |
| 52 Week High | $9.28 | $24.35 |
Technical Indicators
Market Signals| Indicator | GNW | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 69.06 |
| Support Level | $8.14 | $20.35 |
| Resistance Level | $9.12 | $21.39 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | -0.03 | 0.39 |
| Stochastic Oscillator | 24.19 | 94.83 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.